米托蒽醌联合泼尼松治疗激素抵抗性前列腺癌的临床效果

摘要

Objective To explore the clinical effects of mitoxantrone plus prednisone in hormone refractory prostate cancer.Methods 90 cases of patients with hormone refractory prostate cancer were randomly divided into the experiment group and the control group .The experiment group were treated by mitoxantrone plus prednisone ,and the control group were treated by docetaxel plus prednisone .The clinical effects ,bone pain relief effect ,side effects and adverse reactions of the 2 groups were com-pared.Results There was no significant difference in the total effective rate between the experiment group (86.67%) and the control group(84.44%)(P>0.05);The PSA control time of the experiment group (25.33 ±7.57) week were lower than that of the control group(37.88 ±10.26) week (P<0.05);There was no significant difference in the rate of bone pain relief of the ex-periment group(42.22%) and the control group(53.33%)(P>0.05);The incidence of bone marrow suppression of the experi-ment group was 40.00%,the adverse reactions of the experiment group was 6.67%,the incidence of bone marrow suppression of the control group was 53.33%,the adverse reactions of the experiment group was 17.78%,there was no significant difference ( P>0.05).Conclusion Mitoxantrone plus prednisone for hormone refractory prostate cancer has remarkable clinical effects ,the clinical effects is similar as the docetaxel plus prednisone .Mitoxantrone plus prednisone has better effects in bone pain relief ,side effect and adverse reactions .It can improve the clinical effects by alternating the two treatments when one treatment is unsatisfac -tory.Docetaxel plus prednisone can be the save package for mitoxantrone plus prednisone .%目的：探讨米托蒽醌联合泼尼松治疗激素抵抗性前列腺癌的临床效果。方法按照随机数字表法将90例激素抵抗性前列腺癌患者均分为实验组和对照组。实验组采用米托蒽醌联合泼尼松治疗，对照组采用多西他赛联合泼尼松治疗，比较2组患者临床疗效、骨痛缓解效果及毒副作用和不良反应发生情况。结果实验组总有效率为86．67％，与对照组（84．44％）比较，差异无统计学意义（P＞0．05）；实验组患者治疗有效和病情稳定患者的PSA控制时间为（25．33±7．57）周，显著低于对照组（37．88±10．26）周，差异具有统计学意义（P＜0．05）；实验组患者骨痛缓解率为42．22％，与对照组（53．33％）比较，差异无统计学意义（P＞0．05）；实验组患者骨髓抑制发生率为40．00％，不良反应发生率为6．67％，均略低于对照组（53．33％，17．78％），但差异无统计学意义（P＞0．05）。结论米托蒽醌联合泼尼松治疗激素抵抗性前列腺癌临床疗效显著，与多西他赛联合泼尼松相近，但其在骨痛缓解和副作用、不良反应发生情况上略优于多西他赛联合泼尼松。当治疗效果不佳时两种方案交替使用能够有效提高治疗效果，多西他赛联合泼尼松可作为米托蒽醌联合泼尼松的挽救方案。